OncoTricks

Rectum, mediastinum and the first week of chemo, Oct 13, 2026

Locally advanced rectal cancer: the 2026 map

If you remember one thingTest mismatch repair before anything else: if deficient, PD-1 blockade alone; if proficient, the MRI risk decides how much radiation and chemotherapy go before surgery.

First question

Mismatch repair deficient (dMMR / MSI-high)?
yes, 5 to 10%
PD-1 blockade aloneDostarlimab every 3 weeks for 6 months. It produces a complete response in essentially every patient, and most have held it for years without chemotherapy, radiation or surgery.
no, proficient
Proficient: by MRI riskHigh risk (cT4, mesorectal fascia threatened, extramural vascular invasion, lateral nodes, low tumor): total neoadjuvant therapy. Intermediate risk and sphincter-sparing surgery possible: FOLFOX alone, radiation only if the tumor shrinks less than 20% (PROSPECT). Then surgery, or watch-and-wait if the tumor disappears.

In the first 12 patients with dMMR rectal cancer treated with dostarlimab alone, 12 of 12 had a complete clinical response.Cercek 2022. No patient needed chemoradiation or surgery during follow-up. 49 of 49 rectal patients in the 2025 update (Cercek 2025). Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2) are checked on the biopsy by immunohistochemistry: all four present means proficient.

Chemoradiation: the drug during radiation

Capecitabine 825 mg/m2 by mouth twice a dayOn radiation days (Monday to Friday) in the NSABP, PRODIGE and NCCN schedule, for the 5 to 5.5 weeks of long-course radiation (50 to 50.4 Gy); the German non-inferiority trial gave it every day for 38 days. Either way, 825, not 1,000 or 1,250 mg/m2.
Or infusional fluorouracil 225 mg/m2 per dayContinuous pump through the whole course. Capecitabine was non-inferior (Hofheinz 2012) and needs no pump.
Capecitabine 1,000 mg/m2 twice a day, 14 days on, 7 off=The CAPOX dose, not the radiosensitizer dose

Mixing up the two is the classic prescribing error. The radiosensitizer dose is lower because radiation adds its own toxicity to the same bowel.

Total neoadjuvant therapy: three trials, two orders

Goal is organ preservation→Chemoradiation first, chemotherapy after (consolidation)
Goal is to kill distant micrometastases fast (high-risk MRI)→Chemotherapy first (induction), or short-course radiation then chemotherapy
1
RAPIDO (2021). Short-course radiation (5 x 5 Gy) then 6 cycles of CAPOX, then surgery. Disease-related treatment failure at 3 years 24% against 30% with standard chemoradiation. For high-risk tumors on MRI. Caveat from the 5-year data: locoregional recurrence 10% against 6%, so the short-course order is not the one for a tumor you hope to watch (Dijkstra 2023).
2
PRODIGE 23 (2021). 6 cycles of FOLFIRINOX first, then chemoradiation, then surgery. 3-year disease-free survival 76% against 69%. 7-year overall survival 82% against 76% (Conroy 2024).
3
OPRA (2022). Randomized the order: induction (4 months of FOLFOX or CAPOX, then chemoradiation) against consolidation (chemoradiation, then the chemotherapy), then surgery or watch-and-wait by response. Rectum kept at 3 years: 41% with induction, 53% with consolidation. Disease-free survival 76% in both arms.
Sources

Retrieved from PubMed, read on Oct 15, 2026.

  1. Cercek A, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022. doi:10.1056/NEJMoa2201445
  2. Hofheinz RD, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, non-inferiority, phase 3 trial. Lancet Oncol 2012. doi:10.1016/S1470-2045(12)70116-X
  3. Bahadoer RR, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (RAPIDO). Lancet Oncol 2021. doi:10.1016/S1470-2045(20)30555-6
  4. Conroy T, et al. Neoadjuvant FOLFIRINOX and preoperative chemoradiotherapy for locally advanced rectal cancer (PRODIGE 23). Lancet Oncol 2021. doi:10.1016/S1470-2045(21)00079-6
  5. Garcia-Aguilar J, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy (OPRA). J Clin Oncol 2022. doi:10.1200/JCO.22.00032
  6. Cercek A, et al. Nonoperative management of mismatch repair-deficient tumors. N Engl J Med 2025. doi:10.1056/NEJMoa2404512
  7. Schrag D, et al. Preoperative treatment of locally advanced rectal cancer. N Engl J Med 2023. doi:10.1056/NEJMoa2303269
  8. Dijkstra EA, et al. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery (RAPIDO). Ann Surg 2023. doi:10.1097/SLA.0000000000005799
  9. Conroy T, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23. Ann Oncol 2024. doi:10.1016/j.annonc.2024.06.019